Voyager Therapeutics as Q1 results blow past estimates

Voyager Therapeutics

09/05/2023 18:59

** Shares of gene therapy co Voyager Therapeutics  VYGR.O 
jump 32.6% to a 2-1/2 year high of $11.02
    ** Co reports Q1 net income of $2.94 per share, flying by
analysts' average est. of 77 cents per share - Refinitiv
    ** Also posts collaboration revenue of $150.5 mln, while
analysts' had expected $41 mln
    ** Co says Q1 got a boost from strategic collaboration with
Neurocrine Biosciences, as well as Novartis license of novel
TRACER capsids in 2023
    ** As of March 31, co had cash, cash equivalents and
marketable securities of $273.3 million
    ** Shares up ~86% YTD

 (Reporting by Yamini Kalia in Bengaluru)
 ((Yamini.Kalia@thomsonreuters.com))